NewsView printer-friendly version
Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences
- Management will deliver a company presentation at the Jefferies 2019
London Healthcare Conferenceon Thursday, November 21st at 9:20 a.m. GMTtaking place in London, UK.
- Management will deliver a company presentation at the
Piper Jaffray31st Annual Healthcare Conference on Tuesday, December 3rd at 1:30 p.m. ETtaking place in New York, New York.
The audio portion of the presentations will be available on the investors page of the
Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA® in the
VP, Investor Relations & Corporate Affairs
+1 (650) 395-0196
Source: Coherus BioSciences, Inc.